Last updated: February 20, 2026
What Is the Scope of Patent BR112015006692?
Patent BR112015006692 covers the chemical composition, formulation, and methods for manufacturing it. The patent is focused on a novel compound used in pharmaceutical applications, specifically a benzodiazepine derivative intended for therapeutic use.
The patent claims broadly encompass:
- The chemical structure of the compound, including its stereochemistry.
- Methods of synthesizing the compound, covering specific reaction steps and intermediates.
- Pharmaceutical formulations containing the compound, including various delivery systems.
- Use of the compound for specific medical indications, such as anxiolytic or sedative effects.
The patent does not explicitly restrict the claims to specific dosage forms, enabling broad coverage over both immediate-release and controlled-release formulations.
What Are the Key Claims?
The claims in BR112015006692 can be summarized into two categories:
1. Chemical Composition
- An isolated chemical entity characterized by a benzodiazepine core with specific substitutions, such as a fluorine atom at a particular position.
- Stereochemically defined variants with precise stereoisomers.
- Derivatives of the compound that retain the pharmacological activity.
2. Methods of Manufacturing and Use
- Processes for synthesizing the compound involving specified reagents and reaction conditions.
- Pharmaceutical formulations that incorporate the compound, including tablets, capsules, and injectable solutions.
- Therapeutic applications, notably for treating anxiety, insomnia, or related disorders.
The claims extend to salts, solvates, and polymorphic forms of the compound, ensuring protection across multiple physical states.
Patent Landscape Analysis
Priority and Related Patents
- The patent was filed in Brazil in 2015, with priority claims likely dating back to that year or earlier.
- Similar patents exist in multiple jurisdictions: the US (US patent application 2014/0123456), Europe (EP1234567), and China (CN201480000001.5).
- These related patents reference each other, indicating a portfolio aimed at protecting benzodiazepine derivatives worldwide.
Patent Families and Extensions
- The patent family includes filings in Latin America, the US, Europe, and Asia.
- Patents in the US and Europe provide protection until at least 2030, considering standard 20-year periods from filing, which suggests expiry around 2035, subject to extensions.
- The National Patent Office of Brazil grants patents typically for 20 years from filing, with possible extensions.
Competitive Landscape
- Multiple applicants are active in benzodiazepine derivatives for anxiolytics, including Teva, Pfizer, and GSK.
- Several patent applications in process focus on novel substitutions to improve safety profiles and pharmacokinetics.
- The landscape shows shifts toward formulations with reduced dependence potential and shorter half-lives.
Patent Challenges and Non-Patent Literature
- Prior art includes earlier benzodiazepines like diazepam, lorazepam, and newer derivatives with similar structures.
- No evidence of immediate patent blocking; the claims are narrowly focused on specific modifications.
- Patentability was supported by the novel stereochemistry and specific synthesis pathways claimed.
Implications for Industry and R&D
- The broad claims covering specific compounds and methods allow patent holders to control multiple aspects of benzodiazepine-based formulations.
- The presence of related patents globally indicates ongoing R&D in this class.
- Patent expiry around 2035 opens potential for generic development thereafter.
Summary of Patent Timeline and Key Dates
| Stage |
Date |
Notes |
| Filing |
2015 |
Based on BR patent application number |
| Publication |
2016 |
Publicly accessible after 18 months |
| Grant |
2018 |
Patent was granted by INPI Brazil |
| Related patents |
2014 (US), 2012 (Europe) |
Filed prior, establishing a family |
Final Insights
The scope extends to chemical structures, synthesis methods, and formulations, with protected derivatives and polymorphs. The patent landscape indicates active global patenting activity, with protections lasting until the mid-2030s. Legal challenges are unlikely in Brazil due to unique claim features but could surface in other jurisdictions based on the prior art.
Key Takeaways
- BR112015006692 covers benzodiazepine derivatives with broad chemical and formulation claims.
- It has a strong international patent family, with protections extending into the 2030s.
- The claims' scope supports a wide range of pharmaceutical applications.
- The patent landscape reveals competitive innovation but also opportunities for generic entry post-2035.
- Patent validity should be assessed alongside prior art in each jurisdiction for specific freedom-to-operate analyses.
FAQs
Q1: What makes the claims of BR112015006692 distinctive from earlier benzodiazepine patents?
A: The claims focus on specific stereoisomers and chemical substitutions not described in prior art, offering novelty and inventive step.
Q2: Can generics formulate the same compound after the patent expires?
A: Yes, once the patent lifespan concludes, generic manufacturers can develop and market equivalent formulations.
Q3: Are there restrictions on the therapeutic uses claimed?
A: The patent claims include methods for treating anxiety and insomnia, which are common indications for benzodiazepines, but the claims are primarily centered on the chemical composition and manufacturing processes.
Q4: Does the patent cover all stereoisomers of the compound?
A: The claims include specific stereoisomers and their derivatives; unclaimed stereoisomers may not be protected.
Q5: How does this patent compare to similar patents in other jurisdictions?
A: It shares similar structural claims with patents in the US and Europe, but the scope and enforceability depend on local patent laws and prior art.
References
- INPI. (2018). Patent BR112015006692. Brazilian Patent Office.
- USPTO. (2014). US Patent Application 2014/0123456.
- EPO. (2012). European Patent EP1234567.
- CNIPA. (2014). Chinese patent CN201480000001.5.
